RecruitingPhase 1NCT06362265
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
A Single Dose Study to Evaluate the Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
Sponsor
Eli Lilly and Company
Enrollment
22 participants
Start Date
Oct 10, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Eligibility
Min Age: 10 YearsMax Age: 17 Years
Inclusion Criteria4
- Participants with Type 2 Diabetes Mellitus (T2DM) for at least 3 months
- Have Glycated hemoglobin (HbA1c) level of 6.5 percent (%) to 9.5% at screening
- Have a body mass index equal to or less than 45.0 kilograms per square meter (kg/m²)
- Participants are insulin naïve or have been without insulin treatment for at least 3 months prior to screening
Exclusion Criteria7
- Have had a severe hypoglycemia in the past 6 months
- Have a history of renal impairment
- Have had a blood transfusion or severe blood loss within last 90 days
- Have had a significant weight gain or loss of approximately 6% or more within 3 months prior to screening.
- Have a history of an active or untreated malignancy
- Are receiving or received systemic glucocorticoid therapy
- Are currently enrolled in another clinical study trial involving medical research or have participated within the last 30 days in a clinical study involving an investigational product
Interventions
DRUGLY3209590
Administered SC.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06362265
Related Trials
An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea
NCT072325371 location
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
NCT073510583 locations
A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity
NCT071375851 location
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
NCT0711287251 locations
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
NCT0670467214 locations